trending Market Intelligence /marketintelligence/en/news-insights/trending/BkBz9-o7ysyYz3WQ9yaf0Q2 content esgSubNav
In This List

Vanda Pharmaceuticals, Apotex settle patent litigation over schizophrenia drug

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints


Vanda Pharmaceuticals, Apotex settle patent litigation over schizophrenia drug

Vanda Pharmaceuticals said it granted Apotex Inc. and Apotex Corp. a nonexclusive license to manufacture and sell a version of Fanapt in the U.S., effective Nov. 2, 2027.

The license agreement resolves Vanda's patent litigation against Apotex regarding the latter's abbreviated new drug application for its generic version of Vanda's Fanapt.

If Vanda obtains pediatric exclusivity for Fanapt before Nov. 2, 2027, the license, which is subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice, will be effective May 2, 2028.

Fanapt is used in the treatment of schizophrenia in adults.